Technology
At ProdIgY Biotech
We are pioneering IgY-based antibody therapeutics to revolutionize the treatment of liver diseases through microbiome modulation. Our cutting-edge research and technology harness the unique properties of avian-derived antibodies to selectively neutralize harmful microbial components while preserving beneficial gut flora. By targeting the gut-liver axis, we aim to develop first-in-class, non-invasive therapies that address the root causes of alcohol-associated hepatitis (AH).
Immunoglobulin Y: Targeted Antimicrobials for Liver Disease
Both IgG (mammalian) and IgY (avian) antibodies serve as key immunoglobulins responsible for pathogen neutralization and are the most abundantly produced antibodies in their respective species. Unlike IgG, IgY does not activate the mammalian complement system or interact with immune cells via Fc receptors, reducing the risk of unintended immune activation.
Broad Neutralization Capability to Microbiome and Gut Ecology
Avian antibodies (IgY) have demonstrated the ability to generate pathogen-specific neutralization capabilities against viruses, bacteria, fungi, endotoxins, and human secreted immune modulators (cytokines and chemokines)
Specific Targeting
With IgY’s pathogen-specific targeting, Anti-E. faecalis IgY binds and inhibits E. faecalis without disrupting essential microbes like Lactobacillus species.
Polyclonal Therapy
Unlike monoclonal IgG therapies that target a single epitope, polyclonal IgY antibodies engage multiple sites across a pathogen’s surface. This multi-epitope recognition strengthens neutralization and reduces the risk of microbial escape mutations, making IgY well-suited for repeated dosing and long-term therapeutic use.